{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T16:53:33Z","timestamp":1758992013721},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T00:00:00Z","timestamp":1507334400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s11845-017-1684-y","type":"journal-article","created":{"date-parts":[[2017,10,7]],"date-time":"2017-10-07T11:24:53Z","timestamp":1507375493000},"page":"417-421","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Ultra-low dose of intravitreal bevacizumab in retinopathy of prematurity"],"prefix":"10.1007","volume":"187","author":[{"given":"A.","family":"\u015eahin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.","family":"G\u00fcrsel-\u00d6zkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"\u015eahin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. M.","family":"T\u00fcrkc\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Y\u00fcksel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,7]]},"reference":[{"key":"1684_CR1","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1542\/peds.2004-1180","volume":"115","author":"C Gilbert","year":"2005","unstructured":"Gilbert C, Fielder A, Gordillo L et al (2005) Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 115:e518\u2013e525","journal-title":"Pediatrics"},{"key":"1684_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1542\/peds.2007-0644","volume":"121","author":"C Slidsborg","year":"2008","unstructured":"Slidsborg C, Olesen HB, Jensen PK et al (2008) Treatment for retinopathy of prematurity in Denmark in a ten-year period (1996 2005): is the incidence increasing? Pediatrics 121:97\u2013105","journal-title":"Pediatrics"},{"key":"1684_CR3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment For Retinopathy Of Prematurity Cooperative G","year":"2003","unstructured":"Early Treatment For Retinopathy Of Prematurity Cooperative G (2003) Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121:1684\u20131694","journal-title":"Arch Ophthalmol"},{"key":"1684_CR4","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1167\/iovs.13-11765","volume":"54","author":"J Wang","year":"2013","unstructured":"Wang J, Ren X, Shen L et al (2013) Development of refractive error in individual children with regressed retinopathy of prematurity. Invest Ophthalmol Vis Sci 54:6018\u20136024","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1684_CR5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.ophtha.2007.08.050","volume":"115","author":"K Sonmez","year":"2008","unstructured":"Sonmez K, Drenser KA, Capone A Jr et al (2008) Vitreous levels of stromal cell derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology 115:1065\u20131070 e1061","journal-title":"Ophthalmology"},{"key":"1684_CR6","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1001\/jamaophthalmol.2014.5373","volume":"133","author":"W WC","year":"2015","unstructured":"WC W, Lien R, Liao PJ et al (2015) Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity. JAMA Ophthalmol 133:391\u2013397","journal-title":"JAMA Ophthalmol"},{"key":"1684_CR7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ et al (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364:603\u2013615","journal-title":"N Engl J Med"},{"key":"1684_CR8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/ped.12124","volume":"55","author":"A Sahin","year":"2013","unstructured":"Sahin A, Sahin M, Cingu AK et al (2013) Intravitreal bevacizumab monotherapy for retinopathy of prematurity. Pediatr Int 55:599\u2013603","journal-title":"Pediatr Int"},{"key":"1684_CR9","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s00417-014-2867-0","volume":"253","author":"H Yetik","year":"2015","unstructured":"Yetik H, Gunay M, Sirop S et al (2015) Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity\u201427 month follow-up results from Turkey. Graefe\u2019s Arch Clin Exp Ophthalmol 253:1677\u20131683","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"1684_CR10","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/bjo.2008.141481","volume":"92","author":"JE Sears","year":"2008","unstructured":"Sears JE (2008) Anti-vascular endothelial growth factor and retinopathy of prematurity. Br J Ophthalmol 92:1437\u20131438","journal-title":"Br J Ophthalmol"},{"key":"1684_CR11","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1167\/iovs.08-2584","volume":"49","author":"LE Smith","year":"2008","unstructured":"Smith LE (2008) Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Invest Ophthalmol Vis Sci 49:5177\u20135182","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1684_CR12","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1542\/peds.112.5.1016","volume":"112","author":"A Hellstrom","year":"2003","unstructured":"Hellstrom A, Engstrom E, Hard AL et al (2003) Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 112:1016\u20131020","journal-title":"Pediatrics"},{"issue":"Suppl A","key":"1684_CR13","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1016\/j.ghir.2004.03.030","volume":"14","author":"LE Smith","year":"2004","unstructured":"Smith LE (2004) Pathogenesis of retinopathy of prematurity. Growth Hormon IGF Res 14(Suppl A):S140\u2013S144","journal-title":"Growth Hormon IGF Res"},{"key":"1684_CR14","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/j.1651-2227.2011.02445.x","volume":"100","author":"AL Hard","year":"2011","unstructured":"Hard AL, Hellstrom A (2011) On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment\u2014a review. Acta Paediatr 100:1523\u20131527","journal-title":"Acta Paediatr"},{"key":"1684_CR15","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ajo.2011.07.005","volume":"153","author":"T Sato","year":"2012","unstructured":"Sato T, Wada K, Arahori H et al (2012) Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol 153:327\u2013333 e321","journal-title":"Am J Ophthalmol"},{"key":"1684_CR16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang Y, Fei D, Vanderlaan M et al (2004) Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7:335\u2013345","journal-title":"Angiogenesis"},{"key":"1684_CR17","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1097\/IAE.0000000000000535","volume":"35","author":"YR Hong","year":"2015","unstructured":"Hong YR, Kim YH, Kim SY et al (2015) Plasma concentrations of vascular endothelial growth factor in retinopathy of prematurity after intravitreal bevacizumab injection. Retina 35:1772\u20131777","journal-title":"Retina"},{"key":"1684_CR18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1167\/iovs.14-15842","volume":"56","author":"L Kong","year":"2015","unstructured":"Kong L, Bhatt AR, Demny AB et al (2015) Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest Ophthalmol Vis Sci 56:956\u2013961","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1684_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.2015-4450","volume":"137","author":"W LH","year":"2016","unstructured":"LH W, Yang YH, Lin CH et al (2016) Hypotension associated with intravitreal bevacizumab therapy for retinopathy of prematurity. Pediatrics 137:1\u20134","journal-title":"Pediatrics"},{"key":"1684_CR20","first-page":"1848","volume":"16","author":"VS Brar","year":"2010","unstructured":"Brar VS, Sharma RK, Murthy RK et al (2010) Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells. Mol Vis 16:1848\u20131853","journal-title":"Mol Vis"},{"key":"1684_CR21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.brainres.2012.08.014","volume":"1478","author":"MR Romano","year":"2012","unstructured":"Romano MR, Biagioni F, Besozzi G et al (2012) Effects of bevacizumab on neuronal viability of retinal ganglion cells in rats. Brain Res 1478:55\u201363","journal-title":"Brain Res"},{"key":"1684_CR22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bcp.2015.12.017","volume":"103","author":"M Saenz-de-Viteri","year":"2016","unstructured":"Saenz-de-Viteri M, Fernandez-Robredo P, Hernandez M et al (2016) Single and repeated dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions. Biochem Pharmacol 103:129\u2013139","journal-title":"Biochem Pharmacol"},{"key":"1684_CR23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/aos.12266","volume":"92","author":"BC Harder","year":"2014","unstructured":"Harder BC, von Baltz S, Jonas JB et al (2014) Intravitreal low-dosage bevacizumab for retinopathy of prematurity. Acta Ophthalmol 92:577\u2013581","journal-title":"Acta Ophthalmol"},{"key":"1684_CR24","first-page":"e20","volume":"52 Online","author":"AJ Connor","year":"2015","unstructured":"Connor AJ, Papastavrou VT, Hillier RJ et al (2015) Ultra-low dose of intravitreal bevacizumab in the treatment of retinopathy of prematurity. J Pediatr Ophthalmol Strabismus 52 Online:e20\u2013e21","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"1684_CR25","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-3768.2011.02351.x","volume":"91","author":"U Spandau","year":"2013","unstructured":"Spandau U (2013) What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity? Acta Ophthalmol 91:e154","journal-title":"Acta Ophthalmol"},{"key":"1684_CR26","doi-asserted-by":"publisher","unstructured":"Han J, Kim SE, Lee SC et al (2016) Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison. Acta Ophthalmol. \nhttps:\/\/doi.org\/10.1111\/aos.13004","DOI":"10.1111\/aos.13004"},{"key":"1684_CR27","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1089\/jop.2013.0009","volume":"29","author":"J Ahn","year":"2013","unstructured":"Ahn J, Kim H, Woo SJ et al (2013) Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes. J Ocul Pharmacol Ther 29:612\u2013618","journal-title":"J Ocul Pharmacol Ther"},{"key":"1684_CR28","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM et al (2007) Pharmacokinetics of intravitreal bevacizumab (avastin). Ophthalmology 114:855\u2013859","journal-title":"Ophthalmology"},{"key":"1684_CR29","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","volume":"50","author":"H Nomoto","year":"2009","unstructured":"Nomoto H, Shiraga F, Kuno N et al (2009) Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 50:4807\u20134813","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-017-1684-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-017-1684-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-017-1684-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T14:36:41Z","timestamp":1525271801000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-017-1684-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,7]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["1684"],"URL":"https:\/\/doi.org\/10.1007\/s11845-017-1684-y","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,7]]}}}